Article Text

Download PDFPDF
Letter
Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B
  1. Zhongxian Poh1,
  2. Liang Shen2,
  3. Hwai-I Yang3,4,
  4. Wai-Kay Seto5,
  5. Vincent W Wong6,
  6. Clement Y Lin1,
  7. Boon-Bee George Goh1,
  8. Pik-Eu Jason Chang1,7,
  9. Henry Lik-Yuen Chan6,
  10. Man-Fung Yuen5,
  11. Chien-Jen Chen3,8,
  12. Chee-Kiat Tan1,7
  1. 1 Department of Gastroenterology & Hepatology, Singapore General Hospital, Singapore, Singapore
  2. 2 Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
  3. 3 Genomics Research Center, Academia Sinica, Taipei, Taiwan
  4. 4 Graduate Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan
  5. 5 Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
  6. 6 Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, Hong Kong
  7. 7 Duke-NUS Medical School, Singapore, Singapore
  8. 8 Graduate Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan
  1. Correspondence to Adjunct Associate Professor Chee-Kiat Tan, Department of Gastroenterology & Hepatology, Singapore General Hospital, Academia, 20 College Road, Level 3, Singapore 169856, Singapore; tan.chee.kiat{at}sgh.com.sg

Statistics from Altmetric.com

We read with great interest the recent paper by Abu-Amara et al 1 showing that hepatocellular carcinoma (HCC) risk scores derived from Asian cohorts with chronic hepatitis B (CHB) were applicable to a heterogeneous North American patient population as well. They reported that the scoring systems were especially accurate in identifying low-risk patients and as such it is reasonable to use them to guide HCC surveillance recommendations. Out of the five risk scores evaluated, the Chinese University (CU)-HCC and Guide with Age, Gender, HBV DNA, Core promoter mutations and Cirrhosis (GAG-HCC) performed the best.2 ,3 However, HBV DNA titres are needed in both scores and additionally, core mutation determination is needed for even better prediction in the GAG-HCC. Liu et al 4 showed that HBsAg titre is useful in stratifying HCC risk in non-viraemic patients and a recent risk score published by Lin et al 5 included HBsAg titre. These are costly tests that are not universally available.

We have …

View Full Text

Footnotes

  • Contributors ZP and C-KT contributed equally to the data and to the writing of the letter. LS contributed to the statistical analyses, risk model derivation and statistical reporting. VWW, M-FY, B-BGG and P-EJC contributed to the writing of the letter. C-JC, M-FY, HL-YC, H-IY, W-KS and VWW contributed to the validation datasets and to the refinement of the letter. CYL contributed to the data.

  • Competing interests None declared.

  • Ethics approval SingHealth Institutional Review Board.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.